Apitoria Pharma Acquired Wilmington Lab

The pharmaceutical subsidiary purchased A1 Biochem Labs for $15.25 million in cash.

Updated on Oct. 2, 2026 in Healthcare

Isometric editorial illustration of a laboratory centrifuge and glass beakers, representing a pharmaceutical industry acquisition. — Apitoria Pharma has completed the $15.25 million acquisition of A1 Biochem Labs to integrate contract research and manufacturing operations in Wilmington. AI Illustration. Upload story photo >

Live Poll

Do you believe pharmaceutical companies acquiring smaller research labs benefits the overall industry?

Apitoria Pharma Private Limited has finalized the acquisition of Wilmington-based A1 Biochem Labs LLC for $15.25 million. The deal aims to expand the company's contract research capabilities and integrate its existing manufacturing operations.

Why it matters

This move provides Apitoria Pharma with an established research platform, allowing it to move toward creating an integrated contract research, development, and manufacturing organization. The acquisition allows the firm to leverage the acquired lab's portfolio of over 800 completed projects.

A1 Biochem Labs reported annual turnover of $6.35 million in 2023, $9.23 million in 2024, and $5.92 million in 2025. The company maintains a network of over 50 active clients and has completed more than 800 projects.

The players

Apitoria Pharma Private Limited

This pharmaceutical company operates as a subsidiary of Aurobindo Pharma.

A1 Biochem Labs LLC

This Wilmington-based contract research and chemistry services company serves over 50 clients.

Dr. Rajendra Gadikota

He holds a 20% stake in A1 Biochem Labs (India) Private Limited.

The details

The transaction was completed as an arm's length deal and did not require government regulatory approval. Apitoria Pharma, a subsidiary of Aurobindo Pharma, currently holds an 80% stake in the lab, with Dr. Rajendra Gadikota retaining the remaining 20%.

A1 Biochem Labs LLC was incorporated in September 2015.
The lab generated $6.35 million in turnover during 2023.
Turnover reached $9.23 million in 2024 before falling to $5.92 million in 2025.
Aurobindo Pharma announced the completed acquisition on October 2, 2026.

Swimming
Sept. 28
Nir Family YMCA Announced $16 Million Pool Expansion
Robotics
Oct. 2
UNC Wilmington Acquired Humanoid Robot
Violence
Sept. 22
Wilmington Man Charged With Murder and Robbery

Market Landscape

This acquisition follows the broader pharmaceutical industry trend of consolidating research and manufacturing services into integrated CRDMO platforms. The deal strengthens Apitoria Pharma's position against competitors by verticalizing its internal development capabilities.

The acquisition is an internal corporate restructuring that does not immediately change retail drug prices or service availability for the average consumer. Clients currently working with the lab will continue to operate under the integrated structure managed by Apitoria Pharma.

The takeaway

This transaction underscores the importance of scaling research capacity through targeted acquisitions in the life sciences sector. Integrating specialized labs into larger pharmaceutical supply chains is a common strategy to optimize operational efficiency and project delivery.